肾透明细胞癌-话题@MedSci

#肾透明细胞癌#

4篇内容 | 1137人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2193013, encodeId=af7f2193013db, content=<a href='/topic/show?id=7dbc25654c8' target=_blank style='color:#2F92EE;'>#伊匹木单抗#</a> <a href='/topic/show?id=940f11210e24' target=_blank style='color:#2F92EE;'>#纳武利尤#</a> <a href='/topic/show?id=6bc382e5474' target=_blank style='color:#2F92EE;'>#肾透明细胞癌#</a>, objectTitle=读书报告 | PRISM研究：对比标准剂量和改良剂量伊匹木单抗联合纳武利尤治疗肾透明细胞癌的随机对照II期临床研究, objectType=article, longId=816872, objectId=3a788168e253, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-researcher-explores-new-medicine-D5BGJES.jpg, objectUrl=/article/show_article.do?id=3a788168e253, replyNumber=0, likeNumber=19, createdTime=2024-03-13, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=3a788168e253, moduleTitle=读书报告 | PRISM研究：对比标准剂量和改良剂量伊匹木单抗联合纳武利尤治疗肾透明细胞癌的随机对照II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a788168e253)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1210361, encodeId=0311121036123, content=<a href='/topic/show?id=6bc382e5474' target=_blank style='color:#2F92EE;'>#肾透明细胞癌#</a>, objectTitle=ASCO 2020：K药联合仑伐替尼的“可乐组合”在肾透明细胞癌再显威, objectType=article, longId=195028, objectId=3b871950281b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020530/1590848884627_4754896.png, objectUrl=/article/show_article.do?id=3b871950281b, replyNumber=0, likeNumber=0, createdTime=2022-04-11, rootId=0, userName=赛华佗, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b871950281b, moduleTitle=ASCO 2020：K药联合仑伐替尼的“可乐组合”在肾透明细胞癌再显威, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b871950281b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1210360, encodeId=7d831210360c2, content=<a href='/topic/show?id=6bc382e5474' target=_blank style='color:#2F92EE;'>#肾透明细胞癌#</a>, objectTitle=Lancet Oncol：转移性肾透明细胞癌的三种一线治疗方案的疗效和安全性, objectType=article, longId=723824, objectId=cc6fe23824f3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220408/1649399419280_2110107.JPG, objectUrl=/article/show_article.do?id=cc6fe23824f3, replyNumber=0, likeNumber=77, createdTime=2022-04-11, rootId=0, userName=赛华佗, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc6fe23824f3, moduleTitle=Lancet Oncol：转移性肾透明细胞癌的三种一线治疗方案的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc6fe23824f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1206206, encodeId=0928120620614, content=<a href='/topic/show?id=6bc382e5474' target=_blank style='color:#2F92EE;'>#肾透明细胞癌#</a>, objectTitle=肾透明细胞癌预后风险评分(GRANT得分), objectType=scale, longId=2520, objectId=2520, topicUrl=null, isHasObj=0, objectCover=https://static.medsci.cn/public-image/ms-image/c4014af0-a4f3-11ec-a1b8-6123b3ff61ea_企业微信截图_16472234662720.png, objectUrl=https://m.medsci.cn//scale/show.do?id=b00a25200a, replyNumber=0, likeNumber=0, createdTime=2022-03-26, rootId=0, userName=医者仁者, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2520, moduleTitle=肾透明细胞癌预后风险评分(GRANT得分), moduleType=scale, hrefUrl=https://m.medsci.cn/scale/show.do?id=b00a25200a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=996273, encodeId=99bb9962e3ee, content=<a href='/topic/show?id=6bc382e5474' target=_blank style='color:#2F92EE;'>#肾透明细胞癌#</a>中RNF152可被<a href='/topic/show?id=ce9d239823b' target=_blank style='color:#2F92EE;'>#二甲双胍#</a>调控，有意思！！, objectTitle=肾透明细胞癌中RNF152可被二甲双胍通过HNF4A激活并抑制mTOR通路从而下调PD-L1并发挥肿瘤抑制功能, objectType=nsfc, longId=990388, objectId=ef5599038832, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/sci/nsfc_show.do?id=ef5599038832, replyNumber=0, likeNumber=91, createdTime=2021-07-05, rootId=0, userName=小小医者, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef5599038832, moduleTitle=肾透明细胞癌中RNF152可被二甲双胍通过HNF4A激活并抑制mTOR通路从而下调PD-L1并发挥肿瘤抑制功能, moduleType=nsfc, hrefUrl=https://www.medsci.cn/sci/nsfc_show.do?id=ef5599038832)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

肾透明细胞癌

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#伊匹木单抗# #纳武利尤# #肾透明细胞癌#

读书报告 | PRISM研究：对比标准剂量和改良剂量伊匹木单抗联合纳武利尤治疗肾透明细胞癌的随机对照II期临床研究

2024-03-13发表于上海

赛华佗 (审核中...)

前往app查看评论内容

#肾透明细胞癌#

ASCO 2020：K药联合仑伐替尼的“可乐组合”在肾透明细胞癌再显威

2022-04-11

赛华佗 (审核中...)

前往app查看评论内容

#肾透明细胞癌#

Lancet Oncol：转移性肾透明细胞癌的三种一线治疗方案的疗效和安全性

2022-04-11

医者仁者 (审核中...)

前往app查看评论内容

#肾透明细胞癌#

肾透明细胞癌预后风险评分(GRANT得分)

2022-03-26

小小医者 (审核中...)

前往app查看评论内容

#肾透明细胞癌#中RNF152可被#二甲双胍#调控，有意思！！

肾透明细胞癌中RNF152可被二甲双胍通过HNF4A激活并抑制mTOR通路从而下调PD-L1并发挥肿瘤抑制功能

2021-07-05

科室
- - 订阅+
  - 更多科室
工具
服务